TRGN.F Stock Overview

A biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. More details

TRGN.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 30.4% per year for the next 3 years

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Transgene SA Competitors

Enanta Pharmaceuticals

NasdaqGS:ENTA

US$152.3m

MacroGenics

NasdaqGS:MGNX

US$160.7m

Coherus BioSciences

NasdaqGM:CHRS

US$136.0m

Lineage Cell Therapeutics

NYSEAM:LCTX

US$158.7m

Price History & Performance

Summary of share price highs, lows and changes for Transgene
Historical stock prices
Current Share Price	€1.59
52 Week High	€1.85
52 Week Low	€1.30
Beta	0.73
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-14.05%
3 Year Change	-51.67%
5 Year Change	-12.64%
Change since IPO	-87.38%

Recent updates

Shareholder Returns

	TRGN.F	US Biotechs	US Market
7D	0%	0.4%	1.5%
1Y	-14.1%	-2.7%	22.4%

Return vs Industry: TRGN.F underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: TRGN.F underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is TRGN.F's price volatile compared to industry and market?
TRGN.F volatility
TRGN.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.1%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.0%
10% least volatile stocks in US Market	3.0%

Stable Share Price: TRGN.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine TRGN.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1979	141	Alessandro Riva	www.transgene.fr

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.

Transgene SA Fundamentals Summary

How do Transgene's earnings and revenue compare to its market cap?
TRGN.F fundamental statistics
Market cap	US$163.42m
Earnings (TTM)	-US$24.68m
Revenue (TTM)	US$8.73m

18.7x

P/S Ratio

-6.6x

P/E Ratio

Is TRGN.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TRGN.F income statement (TTM)
Revenue	€7.90m
Cost of Revenue	€29.59m
Gross Profit	-€21.69m
Other Expenses	€640.00k
Earnings	-€22.33m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 24, 2024

Earnings per share (EPS)	-0.17
Gross Margin	-274.53%
Net Profit Margin	-282.63%
Debt/Equity Ratio	102.7%

How did TRGN.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/03 12:15
End of Day Share Price	2024/06/06 00:00
Earnings	2023/12/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Transgene SA is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Olga Smolentseva	Bryan Garnier & Co
Brandon Folkes	Cantor Fitzgerald & Co.
Arsene Guekam	CIC Market Solutions (ESN)

TRGN.F Stock Overview

Risk Analysis

Transgene SA Competitors

NasdaqGS:ENTA

US$152.3m

NasdaqGS:MGNX

US$160.7m

NasdaqGM:CHRS

US$136.0m

NYSEAM:LCTX

US$158.7m

Price History & Performance

Recent News & Updates

Transgene SA to Report First Half, 2025 Results on Sep 16, 2025

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

BioInvent Ready for Combination Studies with BT-001

Recent updates

Transgene SA to Report First Half, 2025 Results on Sep 16, 2025

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene SA has completed a Follow-on Equity Offering in the amount of €34.1285 million.

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.